Pathogenetic therapy of bacterial vaginosis - priorities and focus

Abstract

Impaired vaginal microbiocenosis results in various diseases and clinical syndromes. Vaginal microflora imbalance is most often manifested in the form of bacterial vaginosis (BV) caused by the displacement of vaginal lactobacilli with pathogenic obligate anaerobes. The major problem faced by clinicians in the treatment of BV is its tendency towards frequent recurrence. Thus, according to some sources, in 30% of women recurring BV is registered on average within three months after treatment, in 50% - within six months, respectively [1]. However, as the etiology of the syndrome has not been established so far, there is not a unified therapeutic strategy for recurrent BV, neither is it included in any local and global clinical guidelines.